- Home
- VTYX
as 05-16-2024 4:00pm EST
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 329.9M | IPO Year: | 2021 |
| Target Price: | $20.50 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.86 - $40.58 | Next Earning Date: | 05-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Ventyx Biosciences Inc. (VTYX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mohan Raju | VTYX | CEO AND PRESIDENT | Apr 2 '24 | Sell | $5.40 | 4,312 | $23,299.46 | 1,578,250 | SEC Form 4 |
| Krueger Christopher W | VTYX | CHIEF BUSINESS OFFICER | Apr 2 '24 | Sell | $5.40 | 1,651 | $8,921.34 | 284,999 | SEC Form 4 |
| Auster Martin | VTYX | CHIEF FINANCIAL OFFICER | Apr 2 '24 | Sell | $5.40 | 1,405 | $7,591.92 | 24,303 | SEC Form 4 |
| Nuss John | VTYX | Chief Scientific Officer | Dec 20 '23 | Sell | $2.12 | 17,628 | $37,334.34 | 262,118 | SEC Form 4 |
| Mohan Raju | VTYX | CEO and President | Dec 20 '23 | Sell | $2.12 | 58,860 | $124,659.59 | 1,570,719 | SEC Form 4 |
| Krueger Christopher W | VTYX | Chief Business Officer | Dec 20 '23 | Sell | $2.12 | 5,293 | $11,210.04 | 282,119 | SEC Form 4 |
Latest Ventyx Biosciences Inc. News
VTYX Breaking Stock News: Dive into VTYX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 hours ago
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
MT Newswires
8 hours ago
Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise
GlobeNewswire
11 hours ago
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
Insider Monkey
3 days ago
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
GlobeNewswire
7 days ago
Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
GlobeNewswire
14 days ago
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
Zacks
16 days ago
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
GlobeNewswire
2 months ago